07/02/2009
The In Vivo Blog Podcast: An Inside View of Biotech Deals
In Vivo Blog recently interviewed Barbara Kosacz, national head of Cooley's Life Sciences practice. The podcast provides interesting commentary and dealmaking insight for the biotech industry. Listen here.
About this Blog
The In Vivo Blog is home to daily commentary on recent developments in biopharmaceutical business development, R&D, financing, marketing, and policy.
About Barbara Kosacz
Ms. Kosacz has nearly 20 years of experience in counseling clients in the Life Sciences arena. Her clients range from early-stage start ups to large public companies. Ms. Kosacz advises clients on a variety of legal and business issues. Her particular expertise is in complex strategic partnering and joint venture transactions. She also represents both companies and investors and investment banks in private financings, spin-outs, public offerings, and M&A. Some of Ms. Kosacz' recent transactions include Medivation's collaboration with Pfizer for the worldwide development and commercialization of dimebon for Alzheimer's disease, the sale of Ilypsa to Amgen and subsequent spin out of Relypsa from Amgen, Aspreva's novel collaboration with Roche on the development and commercialization of Cellcept® in autoimmune diseases, and ChemoCentrx's $1.5B chemokine drug discovery and development collaboration with GlaxoSmithKline.
View full bio.